Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
38.77
-0.54 (-1.37%)
At close: Dec 5, 2025, 4:00 PM EST
38.51
-0.26 (-0.67%)
After-hours: Dec 5, 2025, 7:58 PM EST
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
205
Market Cap
5.90B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COGT News
- 2 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 21 days ago - Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 24 days ago - Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - GlobeNewsWire
- 24 days ago - Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside - Seeking Alpha
- 25 days ago - Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewsWire
- 25 days ago - Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy - Seeking Alpha
- 25 days ago - Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript - Seeking Alpha
- 25 days ago - Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial - Benzinga